Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.90) by 40 percent. This is a 85.29 percent decrease over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $191.203 million which beat the analyst consensus estimate of $189.193 million by 1.06 percent. This is a 57.42 percent increase over sales of $121.463 million the same period last year.